ArticleStem cells translational medicine2019

Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction.

Jun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.